Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Phase II Bevacizumab + Tax In Advanced Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00027885
- Locations
- πΊπΈ
UH-Southwest, Middleburgh Heights, Ohio, United States
πΊπΈUH-Green Road, South Euclid, Ohio, United States
πΊπΈCase Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-12
- Target Recruit Count
- 392
- Registration Number
- NCT00002700
- Locations
- πΈπ°
Institute of Hematology & Transfusiology, University Hospital, Bratislava, Slovakia
π§πͺHopital Universitaire Erasme, Brussels, Belgium
π§πͺUniversitair Ziekenhuis Antwerpen, Edegem, Belgium
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00049114
- Locations
- πΊπΈ
Albert Einstein College of Medicine, Bronx, New York, United States
Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Registration Number
- NCT00004237
- Locations
- π¬π§
Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom
Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004907
- Locations
- πΊπΈ
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004181
- Locations
- πΊπΈ
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Combination Chemotherapy in Treating Women With Resected Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Registration Number
- NCT00033683
- Locations
- π¬π§
St. Georges Hospital Medical School, London, England, United Kingdom
π¬π§Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom
π¬π§Leicester Royal Infirmary, Leicester, England, United Kingdom
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004896
- Locations
- πΊπΈ
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 56
- Registration Number
- NCT00041132
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-10-25
- Target Recruit Count
- 72
- Registration Number
- NCT00005622
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.